French animal-health company making veterinary medicines and health products for pets and farm animals.
French animal-health company making veterinary medicines and health products for pets and farm animals.
Sells animal medicines to veterinarians directly and through distributors, so growth follows vets' prescribing habits and product registrations in each country. The founding Vetoquinol family still controls the group.
In one line: A smaller French Zoetis/Elanco.
Moat: narrow (regulatory licence, brand, distribution). Established veterinary product registrations and distribution in Europe, but small next to global animal-health leaders.
Headquarters: Lure, France · Founded: 1933 · Employees: 2,501
Size Vetoquinol (VETO.PA) is a France Health Care company (Pharmaceuticals: Major) with a market value of $1.10B, the 130th largest of 206 France companies the cockpit tracks. Shares closed at €86.40 on 18 Nov 2026.
Performance Over six months the shares gained 18.7%, against -7.1% for the median peer and -2.1% for the France market (cap-weighted) — 4th highest of 20 in its peer set.
Growth Revenue fell 0.9% over the last twelve months (peer median -2.3%); the operating margin is 14.8% (peer median 5.4%).
Valuation It trades at 15.5× forward earnings against a peer median of 20.2× (5th cheapest of 13).
Price implies For today's price to make sense, revenue must grow about -4% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is -8 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 7.1 points above its cost of capital (8.0% WACC).
Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | €527M | €526M | €539M | €529M | €540M |
| Revenue growth | — | -3% | +2% | -2% | — |
| Gross profit | €84.6M | €160M | €159M | €158M | €172M |
| EBITDA | €110M | €105M | €102M | €97.3M | €111M |
| Net income | €62.8M | €57.4M | €58.7M | €55.6M | €48.0M |
| Free cash flow | €87.1M | €59.0M | €75.9M | €76.2M | €45.4M |
| Capital expenditure | €18.6M | €20.7M | €17.7M | €19.0M | €22.5M |
| Total debt | n/a | €15.3M | €21.1M | €17.6M | €17.4M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Vetoquinol VETO.PA | $1.10B | +19% | -1% | 15% | 15.5× | -3.6% |
| Zoetis ZTS | $34.8B | +7% | +1% | 37% | 13.8× | -2.9% |
| Elanco Animal Health ELAN | $13.3B | +28% | +12% | 8% | 21.5× | 32.9% |
| Virbac VIRP.PA | $3.20B | -4% | +4% | 15% | 16.6× | 5.8% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | VETO.PA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +8.0% | -2.0% | 3rd highest of 21 |
| 6-month return | +18.7% | -7.1% | 4th highest of 20 |
| Distance from 52-week high | -5.6% | -32.1% | 2nd highest of 21 |
| Revenue growth (TTM) | -0.9% | -2.3% | 8th highest of 17 |
| Operating margin | 14.8% | 5.4% | 6th highest of 18 |
| Forward P/E | 15.5× | 20.2× | 5th cheapest of 13 |
| Growth the price implies (Req g, 7 yrs) | -3.6% | 3.4% | 3rd least demanding of 10 |
| Growth delivered (Del g) | +4.2% | +11.3% | 4th lowest of 10 |
| Hurdle (Req g minus delivered) | -7.8 pp | +4.6 pp | 3rd least demanding of 10 |
| ROIC minus cost of capital | +7.1 pp | -2.8 pp | 4th highest of 18 |
| EV / EBITDA | 7.1× | 14.1× | cheapest of 7 |
| Net debt / EBITDA | -2.0× | -1.3× | 3rd least indebted of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Vetoquinol VETO.PA | France | $1.10B | +19% | -1% | 15% | 15.5× | -3.6% | +4.2% |
| Tianjin Ringpu Bio-technology 300119.SZ | China | $1.11B | -7% | -9% | 11% | 18.1× | 4.9% | +11.3% |
| ST Pharm 237690.KS | South Korea | $1.11B | -51% | +26% | 18% | 27.8× | 4.2% | +21.7% |
| Viyash Scientific VIYASH.NS | India | $1.11B | +3% | +124% | 13% | 32.2× | 36.3% | +20.4% |
| PYC Therapeutics PYC.AX | Australia | $1.09B | +29% | n/a | n/a | n/a | n/a | n/a |
| Symbiotec Pharmalab SYMBIOTEC.NS | India | $1.12B | n/a | n/a | n/a | n/a | n/a | n/a |
| MedinCell MEDCL.PA | France | $1.09B | +4% | -23% | -131% | n/a | n/a | n/a |
| GC Biopharma 006280.KS | South Korea | $1.12B | -10% | -3% | 4% | 4.6× | n/a | n/a |
| North China Pharmaceutical 600812.SS | China | $1.08B | -12% | -21% | 5% | n/a | 1.0% | -4.2% |
| Omeros OMER | United States | $1.08B | +24% | n/a | -56% | 4.3× | n/a | n/a |
| Cosmo CMHC.SW | Switzerland | $1.13B | -30% | -45% | -13% | 418.7× | n/a | n/a |
| Changzhou Qianhong Bio-Pharma 002550.SZ | China | $1.14B | -12% | -2% | 15% | 18.4× | 3.4% | -1.2% |
| Kissei Pharmaceutical 4547.T | Japan | $1.14B | +3% | +6% | 6% | 14.5× | n/a | n/a |
| Everest Medicines 1952.HK | Hong Kong | $1.05B | -20% | +193% | -5% | 23.2× | n/a | n/a |
| Blue Jet Healthcare BLUEJET.NS | India | $1.05B | +19% | -7% | 28% | 30.6× | 40.8% | +13.8% |
| Jiuzhitang 000989.SZ | China | $1.16B | -7% | +46% | 19% | 22.1× | -4.0% | -9.0% |
| Shandong Lukang Pharmaceutical 600789.SS | China | $1.05B | -18% | -7% | 3% | n/a | 2.5% | +6.5% |
| Basilea Pharmaceutica BSLN.SW | Switzerland | $1.04B | +33% | +5% | 24% | 10.5× | -5.6% | +12.7% |
| Savara SVRA | United States | $1.04B | -7% | n/a | n/a | n/a | n/a | n/a |
| Ascentage Pharma Group International 6855.HK | Hong Kong | $1.18B | -34% | +70% | -220% | n/a | n/a | n/a |
| Nektar Therapeutics NKTR | United States | $1.18B | -50% | -17% | -304% | n/a | n/a | n/a |